<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Onderwater, E.E.M.</title>
    <link>http://repub.eur.nl/res/aut/13575/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4697/</link>
      <pubDate>2003-12-17T00:00:00Z</pubDate>
      <description>Objectives
We report on the procedural and six-month results of the first percutaneous and stand-alone study on myocardial repair with autologous skeletal myoblasts.

Background
Preclinical studies have shown that skeletal myoblast transplantation to injured myocardium can partially restore left ventricular (LV) function.

Methods
In a pilot safety and feasibility study of five patients with symptomatic heart failure (HF) after an anterior wall infarction, autologous skeletal myoblasts were obtained from the quadriceps muscle and cultured in vitro for cell expansion. After a culturing process, 296 ± 199 million cells were harvested (positive desmin staining 55 ± 30%). With a NOGA-guided catheter system (Biosense-Webster, Waterloo, Belgium), 196 ± 105 million cells were transendocardially injected into the infarcted area. Electrocardiographic and LV function assessment was done by Holter monitoring, LV angiography, nuclear radiography, dobutamine stress echocardiography, and magnetic resonance imaging (MRI).

Results
All cell transplantation procedures were uneventful, and no serious adverse events occurred during follow-up. One patient received an implantable cardioverter-defibrillator after transplantation because of asymptomatic runs of nonsustained ventricular tachycardia. Compared with baseline, the LV ejection fraction increased from 36 ± 11% to 41 ± 9% (3 months, P = 0.009) and 45 ± 8% (6 months, P = 0.23). Regional wall analysis by MRI showed significantly increased wall thickening at the target areas and less wall thickening in remote areas (wall thickening at target areas vs. 3 months follow-up: 0.9 ± 2.3 mm vs. 1.8 ± 2.4 mm, P = 0.008).

Conclusions
This pilot study is the first to demonstrate the potential and feasibility of percutaneous skeletal myoblast delivery as a stand-alone procedure for myocardial repair in patients with post-infarction HF. More data are needed to confirm its safety.</description>
    </item> <item>
      <title>Validation of the local shortening function as assessed by nonfluoroscopic electromechanical mapping: a comparison with computerized left ventricular angiography. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4850/</link>
      <pubDate>2001-01-30T00:00:00Z</pubDate>
      <description>Background: Nonfluoroscopic electromechanical mapping (NEM) has been proposed as a new technique for the evaluation of electrical and mechanical functioning of the myocardium. In this system, linear local shortening (LLS) is the parameter used for assessment of local mechanical properties. To validate this parameter, we compared LLS with regional wall motion (RWM) data derived from contrast left ventriculograms acquired in the same patients. Methods and results: Angiographic left ventricular RWM was analyzed using the area–length method. The right anterior oblique view was divided in five segments, the left anterior oblique view in two. Through a comparison of enddiastolic and endsystolic areas drawn from a computer-defined central point to the respective wall delineation, RWM was calculated as change in area. In the first approach, we compared area changes to comparable NEM segments. In the second part of the study, LLS values for normokinetic, hypokinetic, akinetic and dyskinetic segments were correlated to the change in angiographic RWM. In the first approach, the overall comparison of segments yielded a correlation coefficient of 0.67 (P&lt;0.0005). In the second part of the study, differences in LLS values between dyskinetic (LLS=−3.68±8.86%), akinetic (2.84±3.96%), hypokinetic (9.35±4.27%) and normokinetic (13.66±7.98%) segments were highly significant (overall ANOVA: P&lt;0.0005). Conclusion: NEM is a powerful tool for invasive electromechanical assessment of myocardial function.</description>
    </item> <item>
      <title>Comparison of mechanical properties of the left ventricle in patients with severe coronary artery disease by nonfluoroscopic mapping versus two-dimensional echocardiograms. (Article)</title>
      <link>http://repub.eur.nl/res/pub/4858/</link>
      <pubDate>2000-11-01T00:00:00Z</pubDate>
      <description>In 40 patients, we compared linear local shortening assessed with nonfluoroscopic electromechanical mapping as a function of regional wall motion with echocardiographic data in a subset of patients with severe coronary artery disease and subsequently decreased left ventricular function. Our study showed that nonfluoroscopic electromechanical mapping can accurately assess regional wall motion. In addition, this study showed a significant decrease in unipolar voltages among segments with declining regional function.</description>
    </item>
  </channel>
</rss>